Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revvity, Inc. Common Stock (NY:RVTY)

98.81 +1.25 (+1.28%)
Streaming Delayed Price Updated: 2:46 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revvity, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Get insights into the top movers in the S&P500 index of Monday's pre-market session.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
Revvity to Hold Earnings Call on Monday, April 28, 2025
From Revvity
Via Business Wire
What's Going On With Revvity Stock Today?
Revvity's stock rose after FDA approval of its Auto-Pure 2400 platform integrated with the T-SPOT.TB test, improving latent TB detection efficiency in labs. 
Via Benzinga
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
From Revvity
Via Business Wire
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Is Revvity Gaining or Losing Market Support?
 
Via Benzinga
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
Maryland Rep. April McClain Delaney Sold Over $54K Worth of A.O. Smith Stock: Here's What You Should Know
 
Via Benzinga
What Does the Market Think About Revvity?
 
Via Benzinga
(RVTY) - Analyzing Revvity's Short Interest
 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Revvity
 
Via Benzinga
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
From Revvity
Via Business Wire
Stay informed with the top movers within the S&P500 index on Wednesday.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Which S&P500 stocks are gapping on Wednesday?
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
From Revvity
Via Business Wire
Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSE:RVTY) and the best and worst... 
Via StockStory
Topics Economy
3 Reasons to Sell RVTY and 1 Stock to Buy Instead
Over the past six months, Revvity’s shares (currently trading at $111) have posted a disappointing 8.5% loss, well below the S&P 500’s 5.1% gain. This was partly due to its softer quarterly results and... 
Via StockStory
Topics Stocks
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
From Revvity
Via Business Wire
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Revvity (NYSE:RVTY) Reports Q4 In Line With Expectations
Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year revenue... 
Via StockStory
Friday's pre-market session: top gainers and losers in the S&P500 index
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
From Revvity
Via Business Wire
Earnings Scheduled For January 31, 2025
 
Via Benzinga
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
From Revvity
Via Business Wire
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
From Revvity
Via Business Wire
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
From Revvity
Via Business Wire
Revvity to Present at J.P. Morgan Healthcare Conference
From Revvity
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.